放疗所致重度淋巴细胞减少预测直肠癌远处转移:免疫保护性放疗的剂量学意义
该回顾性研究纳入2018至2022年接受放疗的161例非转移性直肠癌患者,69.6%发生急性重度淋巴细胞减少(ASL)。ASL与更差的3年无远处转移生存(DMFS)相关(72.6% vs. 84.7%,p=0.034),且为DMFS的独立不良预测因子(p=0.027)。下骨盆低剂量照射V5是ASL的可干预剂量学预测因子,最佳预测截断值为88%。
要点
- ASL发生率为69.6%,与3年DMFS降低相关且为独立不良预后因子。
- 下骨盆V5每增加1%,ASL风险增加(OR 1.06,95%CI 1.02–1.11),截断值88%。
- 基线淋巴细胞计数低和临床T分期高也是ASL的预测因素。
核心结论
- 急性重度淋巴细胞减少与直肠癌放疗后远处转移风险增加相关,下骨盆V5是可干预的剂量学预测因子。
研究设计与样本
- 回顾性分析2018至2022年接受放疗的161例非转移性直肠癌患者,分析临床变量、血清标志物、淋巴细胞计数及骨盆骨髓剂量学。
主要发现
- ASL组3年DMFS为72.6%,非ASL组为84.7%(p=0.034),ASL为DMFS独立预测因子(p=0.027)。
- ECOG评分≥1(p=0.005)、临床N2期(p=0.016)、基线CEA>5 ng/mL(p=0.041)与更差DMFS相关,辅助化疗为保护因素(p<0.001)。
- ASL预测因素包括基线绝对淋巴细胞计数较低(每增加0.1×10⁹/L,OR 0.87,95%CI 0.81–0.93;p<0.001)、临床T分期较高(OR 2.38,95%CI 1.01–5.56;p=0.046)及下骨盆V5较高(每增加1%,OR 1.06,95%CI 1.02–1.11;p=0.005),V5最佳预测截断值为88%。
关键数值与推荐
- 下骨盆V5最佳预测ASL的截断值为88%。
- 基线绝对淋巴细胞计数每增加0.1×10⁹/L,ASL风险OR为0.87(95%CI 0.81–0.93;p<0.001)。
- 临床T分期较高的ASL风险OR为2.38(95%CI 1.01–5.56;p=0.046)。
- 下骨盆V5每增加1%,ASL风险OR为1.06(95%CI 1.02–1.11;p=0.005)。
临床怎么用
- 在直肠癌放疗计划中,可考虑基于ALARA原则限制下骨盆V5以降低ASL风险,支持免疫保护性放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymphopenia is a frequent complication of pelvic radiotherapy and may impair systemic immune surveillance. This study aimed to evaluate the prognostic impact of acute severe lymphopenia (ASL) in rectal cancer and to identify dosimetric predictors relevant to immune-sparing radiotherapy. METHODS: Patients with non-metastatic rectal cancer treated with radiotherapy between 2018 and 2022 were retrospectively reviewed. Clinical variables, serum biomarkers (CEA and NLR), lymphocyte counts, and pelvic bone marrow dosimetry were analyzed. Associations between ASL, distant metastasis-free survival (DMFS), overall survival (OS), and dosimetric metrics were assessed using multivariable models. RESULTS: A total of 161 patients were included, with 69.6% developing ASL. Patients with ASL had inferior 3-year DMFS (72.6% vs. 84.7%; p = 0.034), and ASL remained an independent predictor of poorer DMFS (p = 0.027). ECOG performance status ≥ 1 (p = 0.005), clinical N2 stage (p = 0.016), and baseline CEA > 5 ng/mL (p = 0.041) were also associated with worse DMFS, while adjuvant chemotherapy was protective (p < 0.001). Predictors of ASL included lower baseline absolute lymphocyte count (OR 0.87, 95% CI 0.81–0.93 per 0.1 × 10⁹/L increase; p < 0.001), higher clinical T stage (OR 2.38, 95% CI 1.01–5.56; p = 0.046), and greater low-dose irradiation to the lower pelvis—V5 (OR 1.06, 95% CI 1.02–1.11 per 1% increase; p = 0.005), for which the optimal predictive cut-off was 88%. CONCLUSION: ASL was associated with increased risk of distant metastasis. As baseline immunity and disease burden are non-modifiable, minimizing lower pelvic V5 using as low as reasonably achievable (ALARA)–based planning constraints may help reduce ASL risk and support immune-sparing radiotherapy in rectal cancer.
引用
- Cheng YC, Huang WY, Shen PC, et al. Radiation-induced severe lymphopenia predicts distant metastasis in rectal cancer: dosimetric implications for immune-sparing radiotherapy. Radiat Oncol. 2026. PMID: 41612450. doi:10.1186/s13014-026-02791-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。